[1] World Health Organization. EG.5 initial risk evaluation[EB/OL](2023-08-09)[2023-12-24]. www.who.int/docs/default-source/coronaviruse/09082023eg.5_ire_final.pdf.
[2] 国家生物信息中心. 2019新型冠状病毒全国(不含港澳台)谱系占比[EB/OL](2023-08-17)[2023-12-24]. https://gisaid.org/phylodynamics/china-cn/.
[3] Abbasi J.What to know about EG.5, the latest SARS-CoV-2 "Variant of Interest"[J]. JAMA,2023, 330(10): 900-901.
[4] Dyer O.Covid-19: Infections climb globally as EG.5 variant gains ground[J]. BMJ, 2023, 382: 1900.
[5] 国家卫生健康委,国家中医药局. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 传染病信息,2023,36(1):18-25.
[6] Hoffmann M, Kleine-Weber H, Schroeder S, et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2): 271-280.
[7] Ramesh S, Govindarajulu M, Parise RS, et al.Emerging SARS-CoV-2 variants: A review of its mutations, its implications and vaccine efficacy[J]. Vaccines, 2021, 9(10): 1195.
[8] Yao H, Lu X, Chen Q, et al.Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo[J]. Cell Discov, 2020, 6(1): 76.
[9] Wu P, Chen D, Ding W, et al.The trans-omics landscape of COVID-19[J]. Nat Commun, 2021, 12(1): 4543.
[10] 世卫组织:EG.5被列为需留意的新冠变异株,各国须继续展开监测[EB/OL](2023-08-09)[2023-12-24]. https://news.un.org/zh/story/2023/08/1120522.
[11] Ma W, Fu H, Jian F, et al.Immune evasion and ACE2 binding affinity contribute to SARS-CoV-2 evolution[J]. Nat Ecol Evol, 2023, 7(9): 1457-1466.
[12] Yurkovetskiy L, Wang X, Pascal KE, et al.Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant[J]. Cell, 2020, 183(3): 739-751.
[13] Weber S, Ramirez CM, Weiser B, et al.SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: A time-course study - potential challenge for vaccines and therapies[J]. EMBO Mol Med, 2021, 13(6): e14062.
[14] Giacomo SD, Mercatelli D, Rakhimov A, et al.Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike mutation T478K[J].J Med Virol, 2021, 93(9): 5638-5643.
[15] Parums DV.Editorial: A rapid global increase in COVID-19 is due to the emergence of the EG.5 (Eris) subvariant of omicron SARS-CoV-2[J]. Med Sci Monit, 2023, 29: e942244.
[16] Faraone JN, Qu P, Goodarzi N, et al.Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3[J]. Emerg Microbes Infect, 2023, 12(2): 2270069.
[17] Lubinski B, Fernandes MHV, Frazier L, et al.Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike[J].iScience, 2022, 25(1): 103589.
[18] Zhang H, Deng S, Ren L, et al.Profiling CD8+T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants[J].Cell Rep, 2021, 36(11): 109708.
[19] Chen S, Huang Z, Guo Y, et al.Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies[J]. Cell Discov, 2023, 9(1): 86. |
